Humacyte (HUMA) announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Humacyte. Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS in the vascular trauma indication, the development of the product candidates in Humacyte’s pipeline and for working capital and general corporate purposes. TD Cowen, Barclays and BTIG are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Largest borrow rate increases among liquid names
- HUMA Upcoming Earnings Report: What to Expect?
- Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential
- Humacyte price target lowered to $7.50 from $10 at TD Cowen
- Humacyte announces publication of Budget Impact Model for Symvess